Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGPH20 with Gemcitabine and Abraxane in locally advanced pancreatic cancer
NCT04134468Phase 2Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
A Phase 2 trial of pegvorhyaluronidase alfa in pancreatic ductal adenocarcinoma (PDAC), sponsored by Abramson Cancer Center. Planned start Jan 2020; status: withdrawn.
02
Drugs
pegvorhyaluronidase alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04134468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134468.